Compare RCMT & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | DERM |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.3M | 190.3M |
| IPO Year | 1997 | 2021 |
| Metric | RCMT | DERM |
|---|---|---|
| Price | $28.23 | $6.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $36.00 | $12.67 |
| AVG Volume (30 Days) | 31.1K | ★ 145.7K |
| Earning Date | 04-03-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.38 | ★ 34.72 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | $61,858,000.00 |
| Revenue This Year | $11.89 | $39.72 |
| Revenue Next Year | $12.46 | $63.24 |
| P/E Ratio | $54.76 | ★ N/A |
| Revenue Growth | 5.83 | ★ 10.20 |
| 52 Week Low | $17.26 | $4.31 |
| 52 Week High | $32.50 | $9.56 |
| Indicator | RCMT | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 44.15 |
| Support Level | $27.02 | $5.85 |
| Resistance Level | $29.45 | $6.59 |
| Average True Range (ATR) | 0.71 | 0.38 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 63.85 | 21.71 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.